Please ensure Javascript is enabled for purposes of website accessibility

Quest Diagnostics to Acquire Dignity Health's Lab Outreach Services

By Rich Duprey - Apr 17, 2013 at 10:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Will mark second outreach business acquired in 2013

Diagnostic information specialist Quest Diagnostics (DGX 0.69%) will acquire the lab-related clinical outreach service operations of California-based hospital system Dignity Health, serving doctors and patients in parts of California and Nevada. 

Outreach services are provided by hospitals to physicians and patients outside of a hospital setting.

Quest Diagnostics expects the transaction to be completed in June and anticipates it will be neutral to adjusted earnings in 2013 and modestly accretive to earnings per share in 2014. The company expects it to contribute about half a percentage point to consolidated revenues annually. 

Quest Diagnostics president and CEO Steve Rusckowski said, "This acquisition is consistent with our five-point strategy, which includes delivering disciplined capital deployment and driving 1% to 2% in growth per year through strategically aligned fold-in acquisitions."

If completed, this will mark the second acquisition by Quest of an outreach business in 2013. In January, Quest acquired the clinical and anatomic-pathology outreach laboratory businesses of Massachusetts-based UMass Memorial Medical Center.

Additional terms of the Dignity Health acquisition were not disclosed.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
$141.03 (0.69%) $0.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.